Jack M. DeForrest

Differentiation of Angiotensin–Converting Enzyme (ACE) Inhibitors by Their SelectiveInhibition of ACE in Physiologically Important Target Organs

David W. Cushman, F. L. Wang, Wing Chiu Fung et al. · American Journal of Hypertension · 1989 · 197 citations

Medicine, Pharmacokinetics, Pharmacology +15

.alpha.-Hydroxy Phosphinyl-Based Inhibitors of Human Renin

Dinesh V. Patel, Katherine Rielly-Gauvin, Denis E. Ryono et al. · Journal of Medicinal Chemistry · 1995 · 193 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines

John Krapcho, Chester F. Turk, David W. Cushman et al. · Journal of Medicinal Chemistry · 1988 · 163 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

(Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline, a novel orally active inhibitor of ACE

Donald S. Karanewsky, Michael C. Badia, David W. Cushman et al. · Journal of Medicinal Chemistry · 1988 · 106 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Angiotensin II is a necessary component for the development of hypertension in the two kidney, one clip rat

Jack M. DeForrest, Richard C. Knappenberger, Michael J. Antonaccio et al. · The American Journal of Cardiology · 1982 · 59 citations

Life Sciences, Physiology, Renal Pathophysiology +8